糖尿病・内分泌・代謝内科の研修及び研究実績について
糖尿病・内分泌・代謝内科の研修及び研究実績について
当科の研修について
当施設は日本糖尿病学会認定教育施設Ⅰ、日本内分泌学会認定教育施設に認定されております。当科における研修により日本専門医機構内科専門医、内分泌代謝・糖尿病内科領域専門医および日本糖尿病学会認定専門医を取得することが可能です。基幹施設の研修プログラムの連携施設として専攻医の受け入れも可能です。
当科で現在行っている臨床研究について
当科では下記の臨床研究を行っております。その他、アンケート調査や治験も積極的に行っております。
UMIN000033961 jRCTs031180210
抗VEGF薬(ラニビズマブ)投与下の糖尿病黄斑浮腫を有する2型糖尿病患者を対象としたSGLT2阻害薬(ルセオグリフロジン)の有効性及び安全性に関するグリメピリド対照、多施設共同、ランダム化、非盲検、並行群間比較研究
Effectiveness and safety of Combination therapy of Ranibizumab and LuseOgliflozin in type 2 diabetes with diabetic Macular Edema, a parallel group comparison with the standard Treatment controlled by Glimepiride, multicenter, randomized, open-label trial. (COMET Trial)
UMIN000042242
ビッグデータを用いた糖尿病黄斑浮腫の実態調査および実臨床下でのSGLT2阻害薬の有用性の検討
UMIN000048598
セマグルチド投与下の２型糖尿病合併、高血圧症患者に対するサクビトリルバルサルタンのアジルサルタンに対する降圧作用の非劣性の検証
Non-inferiority trial of Anti-hypertnsive Effect of Sacubitril-Valsartan to Azilsartan In Pateints With Type 2 Daibetes Mellitus Treated With Semaglutide（FERRET）
UMIN000054254
Advanced Hybrid Closed-Loop 使用者におけるSGLT2阻害薬の併用効果についての検討
メディア紹介
国際学会
当科では国内学会だけでなく、海外の学会にも積極的に参加・発表しています。
- ADA：米国糖尿病学会
- EASD：欧州糖尿病学会
- AASD：アジア糖尿病学会
- ATTD：Advanced Technologies & Treatments for Diabetes
- OECD：経済協力開発機構
▶国際学会のぺージへ⇒
| これまで参加した学会・会議（2015年以降） |
開催月 |
開催地 |
| OECD研究者会議 |
2025年10月 |
Paris |
| EASD2025 |
2025年9月 |
Vienna |
| ADA2025 |
2025年6月 |
Chicago |
| AASD2025 |
2025年3月 |
Taipei |
| ATTD2025 |
2025年3月 |
Amsterdam |
| EASD2024 |
2024年9月 |
Madrid |
| ADA2024 |
2024年6月 |
Orlando |
| ATTD2024 |
2023年3月 |
Florence |
| ADA2022 |
2022年6月 |
New Orleans |
| EASD2020 |
2020年9月 |
Online |
| ADA2018 |
2018年6月 |
Orlando |
研究実績（2015年以降）
2025年
- Tatsumi T, Takatsuna Y, Ishibashi R, Koshizaka M, Kaiho T, Oshitari T, Shiko Y, Asaumi N, Yamamoto S, Yokote K, Baba T. Sodium-glucose co-transporter 2 inhibitors reduce the intravitreal anti-VEGF treatment necessity in eyes with early diabetic macular oedema: A post-hoc analysis focusing on the fellow eye of the COMET trial. Diabetes Obes Metab. 2025 Aug 4. Epub ahead of print.
- Baba Y, Maezawa Y, Kondo N, Minamizuka T, Udagawa H, Ide S, Ide K, Teramoto N, Yamaguchi A, Kaneko H, Funayama S, Kato H, Shoji M, Aono K, Miyabayashi M, Sato T, Kitamoto T, Yagyu Y, Ishibashi R, Koshizaka M, Endo Y, Kanda M, Takemoto M, Takayama N, Yasuda K, Kobayashi Y, Yokote K. Tcf21 modulates fibroblast activation and promotes cardiac fibrosis after injury via Pdgfrb signaling. Sci Rep. 2025 Aug 2;15(1):28260.
- Ishibashi R, Takatsuna Y, Koshizaka M, Tatsumi T, Takahashi S, Nagashima K, Ishikawa K, Kaiho T, Asaumi N, Baba T, Yamamoto S, Yokote K. Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trial. Diabetes Obes Metab. 2025 May;27(5):2473-2484.
- Hirayama K, Koshizaka M, Ishibashi R, Shoji M, Horikoshi T, Sakurai K, Yokote K; PRIME‐V Study Group. Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub-analysis of a randomized controlled study. Diabetes Obes Metab. 2025 Apr;27(4):2059-2069.
2024年
- Baba Y, Watanabe S, Hayashi S, Sakai T, Naka M, Kami S, Hirayama K, Koizumi K, Takahashi A, Meguro M, Iga R, Yamanaka Y, Kataoka M, Uchida D, Ishibashi R. Semaglutide improves treatment satisfaction and eating behaviour in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2024 Oct;26(10):4787-4790.
- Ishibashi R, Koshizaka M, Takatsuna Y, Tatsumi T, Maezawa Y, Shiko Y, Inaba Y, Kawasaki Y, Kashiwagi Y, Kawakami E, Yamamoto S, Yokote. Sodium-glucose cotransporter 2 inhibitor therapy reduces the administration frequency of steroid injection in patients with diabetic macular edema: a cohort study using the Japanese health insurance claims database. J Diabetes Investig. 2024 Sep;15(9):1231-1238.
- Sakuma I, Ishibashi R, Matsue K, Vatner DF, Nakamura Y, Yokote K, Tanaka T. Primary adrenal insufficiency due to lymphomatoid granulomatosis in a 32-year-old man. Lancet. 2024 Jun 1;403(10442):e33.
- Ishibashi R, Inaba Y, Koshizaka M, Takatsuna Y, Tatsumi T, Shiko Y, Kashiwagi Y, Maezawa Y, Kawasaki Y, Kawakami E, Yamamoto S, Yokote K. Sodium‐glucose co‐transporter 2 inhibitor therapy reduces the administration frequency of anti‐vascular endothelial growth factor agents in patients with diabetic macular oedema with a history of anti‐vascular endothelial growth factor agent use: A cohort study using the Japanese health insurance claims database. Diabetes Obes Metab. 2024 Apr;26(4):1510-1518.
2023年
- Yoshihara F, Imazu M, Sakuma I, Hiroi Y, Hara H, Okazaki O, Ishiguro C, Izumi C, Noguchi T, Shiraiwa T, Nishioka N, Fujii K, Iwakura K, Tomonaga O, Kobayashi K, Takihata M, Yumoto K, Takase H, Himi T, Shimizu I, Murakami T, Wagatsuma K, Sato K, Hiramatsu T, Akabame S, Hata S, Asakura M, Kawabata T, Omae K, Ito S, Kitakaze M; DAPPER Investigators. DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study): a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trial. EClinicalMedicine. 2023 Nov 27;66:102334.
- Tsukagoshi-Yamaguchi A, Koshizaka M, Ishibashi R, Ishikawa K, Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Terayama R, Hattori A, Takemoto M, Ouchi Y, Maezawa Y, Yokote K; PRIME-V study group. Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: Exploring human metabolites associated with visceral fat reduction. Pharmacotherapy. 2023 Dec;43(12):1317-1326.
- Ishibashi R, Hirayama K, Watanabe S, Okano K, Kuroda Y, Baba Y, Kanayama T, Ito C, Kasahara K, Aiba S, Iga R, Ohtani R, Inaba Y, Koshizaka M, Maezawa Y, Yokote K. Imeglimin-mediated glycemic control in maternally inherited deafness and diabetes. J Diabetes Investig. 2023 Dec;14(12):1419-1422.
- Koshizaka M, Ishibashi R, Ishikawa K, Shoji M, Ide K, Ide S, Kato H, Teramoto N, Terayama R, Maezawa Y, Yokote K; PRIME-V Study Group. Urinary α1 microglobulin level is useful for selecting sodium-glucose transporter 2 inhibitor or metformin for visceral fat reduction in patients with type 2 diabetes. Diabetes Obes Metab. 2023 Jun 29.
2022年
- Tatsumi T, Oshitari T, Takatsuna Y, Ishibashi R, Koshizaka M, Shiko Y, Baba T, Yokote K and Yamamoto S. Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with Diabetes mellitus. Life 2022, 12, 692.
- Koshizaka M, Ishibashi R,Maeda Y, Ishikawa T, Maezawa Y, Takemoto M, Yokote K. Predictive model and risk engine web application for surgical site infection risk in perioperative patients with type 2 diabetes. Diabetology International. 13, 657–664 2022.
2021年
- Yamamoto T, Sakurai K, Watanabe M, Sakuma I, Kanahara N, Shiina A, Hasegawa T, Watanabe H, Iyo M, Ishibashi R. Cyclothymic Temperament is Associated with Poor Medication Adherence and Disordered Eating in Type 2 Diabetes Patients: A Case-Control Study. Diabetes Ther. 2021 Sep;12(9):2611-2624.
- Hiwasa T, Wang H, Goto KI, Mine S, Machida T, Kobayashi E, Yoshida Y, Adachi A, Matsutani T, Sata M, Yamagishi K, Iso H, Sawada N, Tsugane S, Kunimatsu M, Kamitsukasa I, Mori M, Sugimoto K, Uzawa A, Muto M, Kuwabara S, Kobayashi Y, Ohno M, Nishi E, Hattori A, Yamamoto M, Maezawa Y, Kobayashi K, Ishibashi R, Takemoto M, Yokote K, Takizawa H, Kishimoto T, Matsushita K, Kobayashi S, Nomura F, Arasawa T, Kagaya A, Maruyama T, Matsubara H, Tomiita M, Hamanaka S, Imai Y, Nakagawa T, Kato N, Terada J, Matsumura T, Katsumata Y, Naito A, Tanabe N, Sakao S, Tatsumi K, Ito M, Shiratori F, Sumazaki M, Yajima S, Shimada H, Shirouzu M, Yokoyama S, Kudo T, Doi H, Iwase K, Ashino H, Li SY, Kubota M, Tomiyoshi G, Shinmen N, Nakamura R, Kuroda H, Iwadate Y. Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke. BMC Med. 2021 Jun 9;19(1):131.
- Baba Y. Ishibashi R. Takasaki A. Ito C. Watanabe A. Tokita M. Meguro M. Harama T. Hirayama K. Yamamoto T. Nakamura S. Koshizaka M. Maezawa Y. Uchida D. Okajima F.Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Type 1 Diabetes Mellitus on Body Composition and Glucose Variabilities: Single-Arm, Exploratory Trial. Diabetes Ther. 2021 May;12(5):1415-1427.
- Ishibashi R, Baba Y, Kakinuma K, Takasaki A, Hiraga C, Harama T, Yamamoto T, Nakamura S, Koshizaka M, Maezawa Y, Uchida D, Okajima F. Assessing Patient Satisfaction Following Sodium Glucose Co-Transporter 2 Inhibitor Treatment for Type 1 Diabetes Mellitus: A Prospective Study in Japan. Diabetes Ther. 2021 Jan;12(1):453-460
- Koshizaka M, Ishikawa K, Ishibashi R, Takahashi S, Sakamoto K, Yokoh H, Baba Y, Ide S, Ide K, Ishikawa T, Onishi S, Kobayashi K, Takemoto M, Horikoshi T, Shimofusa R, Maezawa Y, Yokote K. Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study. Diabetes Ther. 2021 Jan;12(1):183-196.
- Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K; PRIME-V study group. Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study). J Diabetes Investig. 2021 Feb;12(2):200-206.
2020年
- Takatsuna Y, Ishibashi R, Tatsumi T, Koshizaka M, Baba T, Yamamoto S, Yokote K. Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema. Case Rep Ophthalmol Med. 2020 Nov 12;2020:8867079.
- Ishibashi R, Takatsuna Y, Koshizaka M, Tatsumi T, Takahashi S, Nagashima K, Asaumi N, Arai M, Shimada F, Tachibana K, Watanabe Y, Ishikawa K, Hoshino A, Yamamoto K, Kubota-Taniai M, Mayama T, Yamamoto S, Yokote K. Safety and Efficacy of Ranibizumab and Luseogliflozin Combination Therapy in Patients with Diabetic Macular Edema: Protocol for a Multicenter, Open-Label Randomized Controlled Trial. Diabetes Ther. 2020 Aug;11(8):1891-1905.
- Tanaka A, Taguchi I, Teragawa H, Ishizaka N, Kanzaki Y, Tomiyama H, Sata M, Sezai A, Eguchi K, Kato T, Toyoda S, Ishibashi R, Kario K, Ishizu T, Ueda S, Maemura K, Higashi Y, Yamada H, Ohishi M, Yokote K, Murohara T, Oyama JI, Node K; PRIZE study investigators. Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial. PLoS Med. 2020 Apr 22;17(4):e1003095.
2019年
- Sakamoto K, Furuichi Y, Yamamoto M, Takahashi M, Akimoto Y, Ishikawa T, Shimizu T, Fujimoto M, Takada-Watanabe A, Hayashi A, Mita Y, Manabe Y, Fujii NL, Ishibashi R, Maezawa Y, Betsholtz C, Yokote K, Takemoto M. R3hdml regulates satellite cell proliferation and differentiation. EMBO Rep. 2019 Nov 5;20(11):e47957.
- Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K; PRIME-V Study Group. Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study). Diabetes Obes Metab. 2019 Aug;21(8):1990-1995.
2018年~2015年
- Ishibashi R, Takemoto M, Tsurutani Y, Kuroda M, Ogawa M, Wakabayashi H, Uesugi N, Nagata M, Imai N, Hattori A, Sakamoto K, Kitamoto T, Maezawa Y, Narita I, Hiroi S, Furuta A, Miida T, Yokote K. Immune-mediated acquired lecithin-cholesterol acyltransferase deficiency: A case report and literature review. J Clin Lipidol. 2018 Jul-Aug;12(4):888-897.e2.
- Wang H, Zhang XM, Tomiyoshi G, Nakamura R, Shinmen N, Kuroda H, Kimura R, Mine S, Kamitsukasa I, Wada T, Aotsuka A, Yoshida Y, Kobayashi E, Matsutani T, Iwadate Y, Sugimoto K, Mori M, Uzawa A, Muto M, Kuwabara S, Takemoto M, Kobayashi K, Kawamura H, Ishibashi R, Yokote K, Ohno M, Chen PM, Nishi E, Ono K, Kimura T, Machida T, Takizawa H, Kashiwado K, Shimada H, Ito M, Goto KI, Iwase K, Ashino H, Taira A, Arita E, Takiguchi M, Hiwasa T.Association of serum levels of antibodies against MMP1, CBX1, and CBX5 with transient ischemic attack and cerebral infarction. Oncotarget. 2017 Dec 31;9(5):5600-5613.
- He P, Kawamura H, Takemoto M, Maezawa Y, Ishikawa T, Ishibashi R, Sakamoto K, Shoji M, Hattori A, Yamaga M, Ide S, Ide K, Hayashi A, Tokuyama H, Kobayashi K, Yokote K. Combination of cilostazol and probucol protected podocytes from lipopolysaccharide-induced injury by both anti-inflammatory and anti-oxidative mechanisms. J Nephrol. 2017 Aug;30(4):531-541.
- Ishibashi R, Takemoto M, Akimoto Y, Ishikawa T, He P, Maezawa Y, Sakamoto K, Tsurutani Y, Ide S, Ide K, Kawamura H, Kobayashi K, Tokuyama H, Tryggvason K, Betsholtz C, Yokote K. A novel podocyte gene, semaphorin 3G, protects glomerular podocyte from lipopolysaccharide-induced inflammation. Sci Rep. 2016 May 16;6:25955.
- Hiwasa T, Zhang XM, Kimura R, Ohno M, Chen PM, Nishi E, Ono K, Kimura T, Kamitsukasa I, Wada T, Aotsuka A, Mine S, Takizawa H, Kashiwado K, Takemoto M, Kobayashi K, Kawamura H, Ishibashi R, Yokote K, Nakamura R, Tomiyoshi G, Shinmen N, Kuroda H. Elevated Adiponectin Antibody Levels in Sera of Patients with Atherosclerosis-Related Coronary Artery Disease, Cerebral Infarction and Diabetes Mellitus. J Circ Biomark. 2016 Apr 7;5:8.
- Ishibashi R, Nakamura S, Takemoto M, Mukai C, Yokote K.Helicobacter cinaedi infection in patients with diabetes: a case report. Springerplus. 2015 Feb 10;4:72.
- Sakamoto K, Kuno K, Takemoto M, He P, Ishikawa T, Onishi S, Ishibashi R , Okabe E, Shoji M, Hattori A, Yamaga M, Kobayashi K, Kawamura H, Tokuyama H, Maezawa Y, Yokote K. Pituitary adenylate cyclase-activating polypeptide protects glomerular podocytes from inflammatory injuries. J Diabetes Res. 2015;2015:727152.
２０２５年１１月１７日 更新
